Primary Menu

Skip to content

Home
About Shift
Shift’s Focus
Shift’s Technology
Shift News

Show Header Sidebar Content

Search for:

Twitter Email LinkedIn

Shift Pharmaceuticals

Home »Contact Chris Lorson

Contact Chris Lorson

Shift’s News

FDA grants Orphan Drug status for Shift’s lead compound for SMA May 14, 2020

Follow Us

Twitter Email LinkedIn

Footer Menu

Skip to content

Home
About Shift
Shift’s Focus
Shift’s Technology
Shift News

Copyright © 2020 Shift Pharmaceuticals. All Rights Reserved.

Home
About Shift
Shift’s Focus
Shift’s Technology
Shift News